➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Mallinckrodt
Johnson and Johnson
McKinsey
Moodys

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for AFQ056


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug AFQ056?

AFQ056 is an investigational drug.

There have been 24 clinical trials for AFQ056. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2011.

The most common disease conditions in clinical trials are Parkinson Disease, Dyskinesias, and Syndrome. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Institute on Drug Abuse (NIDA).

There are seventy-four US patents protecting this investigational drug and six hundred and eighty international patents.

Recent Clinical Trials for AFQ056
TitleSponsorPhase
Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056National Institute on Drug Abuse (NIDA)Phase 1
Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056Novartis PharmaceuticalsPhase 1
Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)Novartis PharmaceuticalsPhase 2

See all AFQ056 clinical trials

Clinical Trial Summary for AFQ056

Top disease conditions for AFQ056
Top clinical trial sponsors for AFQ056

See all AFQ056 clinical trials

US Patents for AFQ056

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AFQ056   Get Started Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Get Started Free
AFQ056   Get Started Free Methods of treating sleep disorders Melior Pharmaceuticals II, LLC (Exton, PA)   Get Started Free
AFQ056   Get Started Free Modulators of intracellular chloride concentration for treating fragile X syndrome NEUROCHLORE (Marseilles, FR) INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris, FR) UNIVERSITE AIX MARSEILLE (Marseilles, FR) CENTRE HOSPITALIER UNIVERSITAIRE DE BREST (Brest, FR)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Johnson and Johnson
Mallinckrodt
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.